JAL Launch of “J SOLUTIONS PHARMA CELLS”, a cell transport service for regenerative medicine

【JAL】 Launch of “J SOLUTIONS PHARMA CELLS”, a cell transport service for regenerative medicine ​ Image
URL: JAL Press release: July 8, 2025 Launch of “J SOLUTIONS PHARMA CELLS”, a cell transport service for regenerative medicine ～Supporting next-generation regenerative medicine through transportation and contributing to the realization of well-being for people around the world～ July 7, 2025 ・On Monday, July 7, 2025, JAL will begin offering “J SOLUTIONS PHARMA CELLS,” a cell transport service for regenerative medicine. ・By transporting more quickly and carefully than ever before, we will protect the quality of cell products, which require careful handling. – In response to the rapid development of regenerative medicine in recent years, we will further evolve our existing pharmaceutical transport know-how to meet the emerging need for cell transport and contribute to the advancement and development of the medical field. JAL will start offering “J SOLUTIONS PHARMA CELLS” from Monday, July 7, 2025, to meet the needs for transporting cell products associated with the advancement and development of regenerative medicine technology. This service is an unprecedented, original, custom-made transport service that pursues careful handling and speed of pharmaceuticals, utilizing JAL’s experience and technology, which has positioned pharmaceuticals, a high-value-added cargo, as a strategic priority area.
https://prcdn.freetls.fastly.net/release_image/30684/1269/30684-1269-95131820d043a498709e7bde97055c94-1084×514.png In recent years, with the rapid evolution of regenerative medicine technologies, including iPS cells, cell products are being widely used for many diseases that were previously difficult to treat, including Parkinson’s disease. Unlike conventional medicines, cell products, which are in increasing social demand, are difficult to transport and require fast, safe and reliable transportation. Through this service, JAL will contribute to the realization of a society where new treatments are available all over the world. Features of “J SOLUTIONS PHARMA CELLS” Point 1: Services specialized in cells In addition to the frozen cells we have been handling, we also handle cell-derived products, focusing on live cells that have been difficult to handle due to strict transport time restrictions Point 2: Transport with the highest priority and in the shortest time possible By treating with the highest priority, we can deliver at the earliest 90 minutes before the flight departs and remove at the earliest 90 minutes after the flight arrives Deployed at Narita, Haneda, Kansai and 10 bases in Europe and the United States (further expansion of deployment locations planned in the future) Point 3: Reduce risks during transportation Careful and gentle cargo transportation between aircraft and cargo shed To minimize the risk of contamination, it is possible to transport it separately from other cargo. The JAL Group has built a system for both software and hardware in pharmaceutical transportation, such as obtaining CEIV Pharma certification from the International Air Transport Association (IATA) and establishing dedicated pharmaceutical warehouses at Narita Airport and Kansai Airport, based on high transport quality. According to a forecast by the Cabinet Office, the market size of the regenerative medicine field will expand more than 10 times over the next 10 years, and the importance of specialized transport services in this field is increasing.
https://prcdn.freetls.fastly.net/release_image/30684/1269/30684-1269-ca009c2cdb09cb0a67233a370073f262-553×388.png JAL is actively challenging itself to create value in new business areas in order to solve these social issues. Through the services of “J SOLUTIONS PHARMA CELLS”, we aim to support the development of next-generation regenerative medicine and contribute to the
advancement of the medical field, thereby realizing the well-being of people around the world. More *This email has been sent automatically, so please do not reply.